Trial Outcomes & Findings for Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (NCT NCT02964078)

Last Updated: 2026-04-02

Results Overview

Overall Response According to Immune-related response criteria (irRC). Overall response rate ORR is defined with confirmation of the response status Complete Response (CR) or Partial Response (PR) among the combination treatment population patients; the binomial estimate and its one-sided 95% confidence interval will be reported. CR: Disappearance of all lesions in two consecutive observation not less than 4 weeks apart. PR: ≥50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

27 participants

Primary outcome timeframe

Up to 24 months

Results posted on

2026-04-02

Participant Flow

Participant milestones

Participant milestones
Measure	Pembrolizumab and Interleukin-2 Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Overall Study STARTED	27
Overall Study COMPLETED	27
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Pembrolizumab and Interleukin-2 n=27 Participants Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	17 Participants n=5 Participants
Age, Categorical >=65 years	10 Participants n=5 Participants
Sex: Female, Male Female	5 Participants n=5 Participants
Sex: Female, Male Male	22 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	25 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants
Race (NIH/OMB) White	25 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants
Region of Enrollment United States	27 participants n=5 Participants

PRIMARY outcome

Timeframe: Up to 24 months

Outcome measures

Outcome measures
Measure	Pembrolizumab and Interleukin-2 n=27 Participants Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Overall Response Rate (ORR)	70.4 percentage of participants Interval 54.6 to 100.0

SECONDARY outcome

Timeframe: Up to 24 months

Analysis: Overall Survival (OS) of ITT patients using Kaplan-Meier estimate, counting from the eligible date to death from any cause, or censored on end of known follow up, either within this study or in the Prometheus Laboratories sponsored PROCLAIM registry (PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy, NCT01415167).

Outcome measures

Outcome measures
Measure	Pembrolizumab and Interleukin-2 n=27 Participants Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Overall Survival (OS) of Intent to Treat (ITT) Population	1 proportion of participants Interval 0.871 to 1.0

SECONDARY outcome

Timeframe: Up to 24 months

Progression-free survival (PFS) of ITT patients using Kaplan Meier estimate, from the confirmed eligible date to the first occurrence of disease progression or death, from any cause, or lost to follow up, whichever is earliest; or censored at last follow-up during study. Progressive Disease (PD): At least 25% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 weeks apart.

Outcome measures

Outcome measures
Measure	Pembrolizumab and Interleukin-2 n=27 Participants Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Progression Free Survival (PFS)	.630 proportion of participants Interval 0.421 to 0.781

Adverse Events

Pembrolizumab and Interleukin-2

Serious events: 17 serious events

Other events: 25 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Pembrolizumab and Interleukin-2 n=27 participants at risk Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Cardiac disorders Atrial fibrilation	11.1% 3/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Atrial flutter	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Supraventricular tachycardia	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Ventricular tachycardia	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Nausea	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Vomiting	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Flu like symptoms	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Infusion related reaction	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Creatinine increased	11.1% 3/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypocalcemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyponatremia	14.8% 4/27 • Number of events 8 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified - Other	11.1% 3/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Edema cerebral	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Headache	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Intracranial hemorrhage	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Nervous system disorders - Other	7.4% 2/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Renal and urinary disorders Acute kidney injury	22.2% 6/27 • Number of events 6 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Renal and urinary disorders Renal and urinary disorders - Other	29.6% 8/27 • Number of events 8 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Dyspnea	11.1% 3/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Capillary leak syndrome	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Hypotension	25.9% 7/27 • Number of events 12 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Blood bilirubin increased	11.1% 3/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Alanine aminotransferase increased	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Aspartate aminotransferase increased	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Blood and lymphatic system disorders Anemia	3.7% 1/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Lymphocyte count decreased	25.9% 7/27 • Number of events 19 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypophosphatemia	29.6% 8/27 • Number of events 14 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Hypertension	11.1% 3/27 • Number of events 6 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Vascular disorders - Other	7.4% 2/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Blood and lymphatic system disorders Leukocytosis	18.5% 5/27 • Number of events 10 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Electrocardiogram QT corrected interval prolonged	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypermagnesemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypoalbuminemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Fatigue	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypokalemia	7.4% 2/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Musculoskeletal and connective tissue disorders Arthralgia	11.1% 3/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Hypoxia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Abdominal Pain	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Pain	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyperglycemia	3.7% 1/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Dehydration	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Nystagmus	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Adult respiratory distress syndrome	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyperuricemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment

Other adverse events

Other adverse events
Measure	Pembrolizumab and Interleukin-2 n=27 participants at risk Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
Investigations Creatinine increased	25.9% 7/27 • Number of events 12 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Lymphocyte count decreased	25.9% 7/27 • Number of events 19 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Blood bilirubin increased	18.5% 5/27 • Number of events 6 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Urine output decreased	11.1% 3/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Alanine aminotransferase increased	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Electrocardiogram QT corrected interval prolonged	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Investigations - Other	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Aspartate aminotransferase increased	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Investigations Weight gain	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypophosphatemia	29.6% 8/27 • Number of events 14 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyponatremia	18.5% 5/27 • Number of events 9 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypokalemia	7.4% 2/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Anorexia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Dehydration	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyperglycemia	3.7% 1/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypermagnesemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyperuricemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hyperalbuminemia	3.7% 1/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypocalcemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Hypoglycemia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Metabolism and nutrition disorders Obesity	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Sinus tachycardia	29.6% 8/27 • Number of events 10 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Atrial fibrillation	14.8% 4/27 • Number of events 5 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Chest pain - cardiac	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Ventricular tachycardia	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Asystole	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Atrial flutter	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Cardiac disorders - Other	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Sinus bradycardia	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Cardiac disorders Supraventricular tachycardia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Hypotension	14.8% 4/27 • Number of events 6 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Hypertension	14.8% 4/27 • Number of events 8 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Capillary leak syndrome	11.1% 3/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Vascular disorders Vascular disorders - Other	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Renal and urinary disorders Renal and urinary disorders - Other	22.2% 6/27 • Number of events 7 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Renal and urinary disorders Acute kidney injury	22.2% 6/27 • Number of events 6 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Skin and subcutaneous tissue disorders Rash maculo-papular	22.2% 6/27 • Number of events 9 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Skin and subcutaneous tissue disorders Dry skin	11.1% 3/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Skin and subcutaneous tissue disorders Pruritus	11.1% 3/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders -Other	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Fatigue	11.1% 3/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Fever	11.1% 3/27 • Number of events 4 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Edema limbs	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Pain	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Chills	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders Flu like symptoms	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
General disorders General disorders and administration site conditions -Other	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Diarrhea	7.4% 2/27 • Number of events 3 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Nausea	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Vomiting	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Abdominal pain	3.7% 1/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Constipation	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Dry mouth	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Gastrointestinal disorders Dysphagia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Blood and lymphatic system disorders Leukocytosis	22.2% 6/27 • Number of events 10 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Blood and lymphatic system disorders Anemia	3.7% 1/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Dyspnea	22.2% 6/27 • Number of events 6 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Adult respiratory distress syndrome	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Hypoxia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Pneumonitis	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Respiratory, thoracic and mediastinal disorders Respiratory, thoracic and mediastinal disorders - Other	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Headache	14.8% 4/27 • Number of events 5 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Intracranial hemorrhage	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Dizziness	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Facial muscle weakness	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Lethargy	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Nervous system disorders - Other	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Nystagmus	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Nervous system disorders Tremor	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Musculoskeletal and connective tissue disorders Arthralgia	14.8% 4/27 • Number of events 7 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Musculoskeletal and connective tissue disorders Myalgia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Infections and infestations Infections and Infestations - Other	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Infections and infestations Upper respiratory infection	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified - Other	7.4% 2/27 • Number of events 2 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Endocrine disorders Hyperthyroidism	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Eye disorders Blurred vision	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment
Reproductive system and breast disorders Dyspareunia	3.7% 1/27 • Number of events 1 • Adverse events recorded from Cycle 1 day 1 through 30 days after cessation of treatment

Additional Information

Jad Chahoud MD, MPH

Moffitt Cancer Center

Phone: 813-745-6926

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place